Junqiang Dai, Ph.D.

Professional Background

Dr. Junqiang Dai is a Research Assistant Professor in the Department of Biostatistics and Data Science at the University of Kansas Medical Center, where he completed his PhD in Biostatistics. Before becoming a faculty member, he served as a Senior Research Analyst/Statistician II, gaining substantial expertise in statistical analysis and research methodology. His role involves collaborative research across diverse medical fields, alongside teaching and conducting methodological research. His primary research interests focus on early-phase clinical trial design and adaptive clinical trial design with time-to-event endpoints.

• PhD, Biostatistics, University of Kansas Medical Center, Kansas City, Kansas
• MS, Biostatistics, University of Kansas Medical Center, Kansas City, Kansas
• BS, Life Science and Biotechnology, Wuhan University, Wuhan, Hubei

• Dai Junqinag, He Jianghua, Phadnis Milind A. 2024. Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution. Contemporary Clinical Trials Communications, 101344
• Rasu Rafia S, Phadnis Milind A, Xavier Christy, Dai Junqiang, Hunt Suzanne L, Jain Nishank. 2024. P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis. Kidney International Reports
• Saeed Anwaar, Park Robin, Pathak Harsh, Al-Bzour Ayah Nedal, Dai Junqiang, Phadnis Milind, Al-Rajabi Raed, Kasi Anup, Baranda Joaquina, Sun Weijing, others. 2024. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature Communications, 15 (1), 1533
• Sun Weijing, Veeramachaneni Nirmal, Al-Rajabi Raed, Madan Rashna, Kasi Anup, Al-Kasspooles Mazin, Baranda Joaquina, Saeed Anwaar, Phadnis Milind A, Godwin Andrew K, others. 2023. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.. Cancer Medicine
• Saeed Anwaar, Park Robin, Dai Junqiang, Al-Rajabi Raed, Kasi Anup, Baranda Joaquina, Williamson Stephen, Saeed Azhar, Ripp Jacob, Collins Zachary, others. 2023. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Reports Medicine
• Jain Nishank, Corken Adam, Arthur John M, Ware Jerry, Arulprakash Narenraj, Dai Junqiang, Phadnis Milind A, Davis Otis, Rahmatallah Yasir, Mehta JL, others. 2023. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascular Pharmacology, 107143